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1. Introduction 
Since ancient times humanity has depended on the diversity of plant resources for food, 
clothing, shelter, and traditional medicine to cure myriads of ailments. Early humans 
recognized their dependence on nature in both health and illness. Physical evidence of the 
use of herbal remedies has been found some 60,000 years ago in a burial site of a 
Neanderthal man uncovered in 1960 in a cave in northern Iraq. Here, scientists found 
great quantities of plant pollen, some of which came from medicinal plants still used 
today. The first written records detailing the use of herbs in the treatment of illness are in 
the form of Mesopotamian clay tablet writings and Egyptian papyrus. Led by instinct, 
taste and experience, primitive men and women treated illness by using plants, animal 
parts, and minerals that were not part of their usual diet. Primitive people learned by trial 
and error to distinguish useful plants with beneficial effects from those that were toxic or 
non-active, and also which  combinations or processing methods had to be used to gain 
consistent and optimal results. Even in ancient cultures, tribal people methodically 
collected information on herbs and developed well-defined herbal pharmacopeias. 
Traditional medicine evolved over centuries, depending on local flora, culture, and 
religion. 
Nature has been a source of medicinal agents for thousands of years, and an impressive 
number of modern drugs have been isolated from natural sources, particularly plants and 
with many based on their use in traditional medicine. By using medicinal chemistry and 
combinatorial chemical and biosynthetic technology, novel natural product leads will be 
optimized on the basis of their biological activities to yield effective chemotherapeutic and 
other bioactive agents (Cragg et. al. 2005). 
During the past decades, public interest in natural therapies, namely herbal medicine, has 
increased dramatically not only in developing countries but mainly in industrialized 
countries (Calixto, 2000). The market for ayurvedic medicines is estimated to be expanding 
at 20% annually. Sales of medicinal plants have grown by nearly 25% in India during 1987-
96, the highest rate of growth in the world. The global trade in medicinal plants is of the 
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order of US$ 800 million per year. Export statistics available between 1992 and 1995 indicate 
that India exported about 32,600 tonnes of crude drugs valued at $US 46 million. China with 
exports of over 120,000 tons per annum (US$ 264.5 million) and India with over 32,000 tons 
per annum dominate the international market. The annual export of medicinal plants from 
India is valued at Rs. 1200 million.  Two of the largest users of medicinal plants are China 
and India. Traditional Chinese Medicine (TCM) uses over 5000 plant species, India uses 
about 7000. According to Export Import Bank, the international market for medicinal plant 
related trade is to the tune of US$ 60 billion having a growth rate of 7% per annum. China's 
share in world herbal market is US$ 6 billion while India's share is only US$1 billion. The 
World Bank estimated global trade in medicinal and aromatic plants and their products at 
US $ 5 trillion by 2050 AD. Global herbal market is around $ 70.5 billion with an average 
annual growth of 10-12% per annum. In European union, it contributes to around 45%($ 32 
billion), rest of the Europe 4% (2.8 billion), North America 10% (7.8 billion), Asia 19% (12.2 
billion) and others 7% (4.6 billion) (Handa, 2007). 
Complimentary alternative medicine therapies continue to gain popularity as modalities for 
the treatment of atopic disorders, such as asthma, allergic rhinitis, and atopic dermatitis. In 
Chinese, Japanese, Korean, Indian, and Western cultures, herbal therapies are commonly 
used for allergies. Although well controlled scientific studies have been performed for many 
of the Asian herbal therapies, and some basic studies have been performed for various 
herbal components (active ingredients), more needs to be done to assess the composite 
effects of many of these remedies (Zuckerman et al., 2002) Complementary and alternative 
medicines (CAMs) are used in more than 80% of the world’s population and are becoming 
an increasing component of the US health care system, with more than 70% of the 
population using CAM at least once and annual spending reaching as much as $34 billion.  
 
 
 
Fig. 1. Annual CAM publications related to allergy and immunology. The numbers of 
articles published and available for search through PubMed using the search terms 
complementary medicine and immunology, asthma, allergy, autoimmune, hypersensitivity, 
or inflammation are shown. 
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Since the inception of the National Centre for Complementary and Alternative Medicine, 
there has been an enormous increase in the number of basic science and therapy-based 
clinical trials exploring CAM. The subspecialty of allergy and immunology represents a 
particularly fertile area with a large number of CAM therapies that have been shown  
to affect the immune system. Research has shown that phytoconstituents such as 
resveratrol, quercetin, and magnolol may affect transcription factors such as nuclear 
factor-kB and the signal transducer and activator of transcription/Janus kinase pathways 
with resultant changes in cytokines and inflammatory mediators. Clinically, there have 
been hundreds of trials looking at the effect of CAM on asthma, allergic rhinitis, and 
atopic dermatitis.  
2. Bronchitis and related diseases 
Bronchitis is described as the inflammation of the bronchial tubes (inflammation = itis). The 
inflammation causes swelling of the lining of these breathing tubes, narrowing the tubes 
and promoting secretion of inflammatory fluid. 
Bronchiolitis is a term that describes inflammation of the smaller bronchi referred to as 
bronchioles. In infants, this is usually caused by respiratory syncytial viruses (RSV) and 
affects the small bronchi and bronchioles more than the large. In adults, other viruses as 
well as some bacteria can cause bronchiolitis and often manifest as persistent cough and at 
times production of small plugs of mucus. 
Acute bronchitis describes the inflammation of the bronchi usually caused by a viral 
infection, although bacteria and chemicals may also cause acute bronchitis.  Acute bronchitis 
is a cough that begins suddenly, usually due to a viral infection involving the larger 
airways. Colds (also known as viral upper airway infections) often involve the throat 
(pharyngitis) and nasal passages, and at times the larynx (resulting in a diminished hoarse 
voice, also known as laryngitis). Symptoms can include a runny nose, nasal stuffiness, and 
sore throat. Croup usually occurs in infants and young children and involves the voice box 
and upper large airways (the trachea and large bronchi). 
Chronic bronchitis for research purposes is defined as a daily cough with sputum 
production for at least three months, two years in a row. Chronic bronchitis is a diagnosis 
usually made on the basis of clinical findings of a long term persistent cough usually 
associated with tobacco abuse. From a pathologic standpoint, characteristic microscopic 
findings involving inflammatory cells seen in airway tissue samples make the diagnosis. 
When referring to pulmonary function testing, a decrease in the ratio of the volume of 
airflow at 1 second when compared to total airflow is less than 70%. This confirms the 
presence of obstructive airways disease of which chronic bronchitis is one type. Certain 
findings can be seen on imaging studies (chest X-ray, and CT or MRI of the lungs) to 
suggest the presence of chronic bronchitis; usually this involves an appearance of 
thickened tubes. 
Asthma: Asthma is a chronic inflammatory disease that affects about 300 million people 
worldwide, a total that is expected to rise to about 400 million over the next 15–20 years. 
Most asthmatic individuals respond well to the currently available treatments of inhaled 
corticosteroids and β-adrenergic agonists; however, 5–10% has severe disease that responds 
poorly. Asthma is a life threatening respiratory condition that causes: 
1. The lining of the airways to become swollen 
2. The body produces thick mucous 
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3. Tightness of the muscle around the airways. 
This combination of problems interferes with the exchange of oxygen and carbon dioxide in 
the lungs Figure 2. 
 
 
 
 
 
 
 
 
Fig. 2. Bronchitis and related diseases 
3. Symptoms 
 Breathlessness 
 Wheezing     
 Sputum Production 
 Difficulty in talking 
 Dyspnoea 
 Tightness of Neck Muscle 
 Coughing after physical activity 
 Whistling Sound while breathing 
 Frequent coughing 
 Feeling Frightened, exhaustion 
 Chest Tightness 
 Greyish or bluish colouring of lips 
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4. Trigors or mediators responsible for bronchitis and related diseases 
 
List of agents Events triggering asthma 
Respiratory infection 
Respiratory syncytial virus (RSV), Rhinovirus, Influenza
and Para-influenza virus, Mycoplasma pneumonia bacteria 
Allergens 
Airborne pollens (grass, trees, weeds), house-dust, mites, 
animal dander, cockroaches, fungal spores 
Environment 
Cold air, fog, ozone, sulfur dioxide, nitrogen, tobacco 
smoke, wood smoke 
Emotions Anxiety, stress, laughter 
Exercise particularly in cold, dry climate 
Drugs/preservatives 
Aspirin, NSAIDs, Sulfites, Benzalkonium chloride,  
blockers, 
Occupational stimuli 
Bakers (flour dust), farmers (hay mold), spice and enzyme 
workers, printers (Arabic gum), chemical workers 
(azodyes, anthraquinone, ethylenediamine, toluene, 
diisocyanates, PVC), plastics, rubber and wood workers 
(formaldehyde, western cedar, dimethylethanolamine, 
anhydrides) 
Table 1. List of agents responsible as triggers in bronchitis and related diseases  
 
 
Fig. 3. Agents responsible as triggers in bronchitis and related diseases 
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5. Tradtional medicines as bronchodilator and used in related diseases 
 
Plants 
Vernacular 
name 
Traditional Uses 
Adhatoda zeylanica 
Medic. 
F: Acanthaceae 
Addasaramu 
2-3 spoonfuls of leaf extract given for about a 
month. 
Ailanthus excelsa Roxb. 
F: Simaroubaceae 
Peddamanu 
Bark decoction administered orally in 2 spoonfuls 
thrice a day for about one month 
Azima tetracantha Lamk.
F:Salvadoraceae 
Uppi Teega 
Leaf juice administered orally,2 spoonfuls, twice a 
day for about 20 days. 
Bambusa arundinacea 
(Retz.) Willd. 
F: Gramineae 
Veduru 
Leaf decoction administered orally, 3 spoonfuls, 
twice a day for about one month. 
Barleria cuspidata 
Heyne.ex Nees 
F: Acanthaceae 
Nelambram 
Root decoction administered orally, 2 spoonfuls 3-4 
times a day for 7days. 
Barleria prionitis L. 
F: Acanthaceae 
Mulla Gorinta
Stem ground with honey and ginger ,made into 
dry pillets and administered , 2 pillets, twice a day 
for amonth. 
Blumea mollis (D.Don.) 
Merr. 
F: Compositae 
Kukka Pogaku
Dried leaves smoked with wrapping leaves of 
Diospyros mealanoxylon 
Boerhavia diffusa L. 
F: Nyctaginaceae 
Atika Mamidi
Root extract is administered orally, one spoonful a 
day for 15days. 
Calotropis procera (Ait.) 
R.Br. 
F: Asclepiadaceae 
Jilledu 
Flower powder mixed with honey and 
administered, 2 spoonfuls, twice a day for a month 
Cassia fistula L. 
F: Leguminosae, 
Sf; Caesalpinoideae 
Rela 
Fruits ground with roots of Hemidesmus and the 
paste administered in 10g twice a day about 20 d. 
Curculigo orchioides 
Gaertn. 
F: Hypoxidaceae 
Nela Tadi 
Rhizome extract administered, 2 spoonfuls, twice a 
day for about 2 months or till cure. 
Datura metal L. 
F: Solanaceae 
Erri Ummetta
Fruits ground and made into small pills with 
honey and   2 pills taken twice a day for about 3 
months 
Desmodium triflorum (L.) 
DC. 
F:Leguminosae,  Sf; 
Papilionatae 
Munta Manda
Root decoction given in 2 spoonfuls twice a day for 
about 10d. 
Lepidagathis cristata 
Willd. 
F: Acanthaceae 
Suryakanta 
Powder of shade dried whole plant mixed with 
honey in 2 spoonfuls is administered twice a day 
for a bout 20d. 
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Plants 
Vernacular 
name 
Traditional Uses 
Nerium oleander (L.) 
F: Apocynaceae 
Ganneru. 
Flowers ground with jaggery and the extract 
administered in 2 spoonfuls twice a day for about 2 
months. 
Opuntia stricta (Haw.) 
Haw. 
F: Cactaceae 
Naga Phanni 
Fruits are warmed and the juice given in 2 
spoonfuls thrice a day for about 2 weeks. 
Passiflora foetida L. 
F: Passifloraceae 
Tella Jumiki 
Leaf decoction administered in 2 spoonfuls with 
fruit juice of Terminalia chebula thrice a day for 
about one 
month. 
Pergularia daemia 
(Forssk.) Chiov. 
F: Asclepiadaceae 
Dustapa teega
Leaf decoction taken in 2 spoonfuls 2-3 times a day 
for about 15d. 
Phyllanthus emblica L. 
F: Euphorbiaceae 
Pedda Usiri 
Fruits ground with tubers of Cyperus rotundus and 
leaves of Tinospora cordifolia and the paste 
administered 
with honey in 2 spoonfuls twice a day for about 
one month. 
Phyllanthus reticulatus 
Poir. 
F: Euphorbiaceae, 
Puli Chettu 
Root decoction with honey administered in 2 
spoonfuls twice a day for one month. 
Piper longum L. 
F: Piperaceae 
Pippallu 
Whole plant ground with leaves of Adhatoda 
zeylanica and made into powder. A spoonful of 
powder is taken once in day for 20d. 
Portulaca quadrifida L. 
F: Portulacaceae 
Sanna pappu 
koora 
Whole plant extract mixed with honey and 
administered in 2 spoonfuls thrice a day for about 
20d. 
Solanum surattense 
Burm.f. 
F: Solanaceae 
Mulla 
Root decoction administered in 2-3 times a day for 
about one month. 
Tragia involucrata L. 
F: Euphorbiaceae 
Durada gondi
Root powder cigared with leaves if Diospyros 
melanoxylon and smoked to reduce suffering 
Tylophora fasciculata 
Ham. 
F:ASclepiadaceae 
Veripala teega
Tender leaf juice administered in 2 spoonfuls twice 
a day for 20 – 30d. 
Vicoa indica (L.) DC. 
F: Compositae 
Adavi poddu 
tirugudu 
Leaf juice administered in 2 spoonfuls twice a day 
for 15d 
Vitex negundo L. 
F: Verbenaceae 
Vavili 
Leaf juice with dried powder of Zingiber officinale 
given in 2 spoonfuls twice a day for about 20d. 
Zaleya decandra (L.) 
Burm.f.F: Aizoaceae 
Tella garijelu 
Root juice administered in 2 spoonfuls twice a day 
for about 20d. 
Table 2. List of traditional medicinal plant drugs for the treatment of bronchial diseases 
(Madhu et al., 2010). 
www.intechopen.com
 Bronchitis 
 
178 
6. Reported bronchodilators from medicinal plant drugs 
 
Plant Part used 
Extract/Active 
principle 
Probable action in asthma 
Achyranthus 
aspera 
Roots Oily preparation 
Decreased ESR, Decreased total 
Eosinophil count. (Sharadini,1985) 
Adhathoda vasica 
Leaves 
Roots 
Alkaloids 
Bronchodilator, Anti- anaphylactic 
(Sharadini,1985) 
Albizzia lebbeck 
Flower, 
Bark 
Decoction 
Anaphylaxis, Histamine Induced 
Bronchospsm (Tripathi & Das,1977) 
Belamcand 
chinensis 
Leaves, 
Rhizome 
50% Ethanolic 
Extract 
Histamine Induced Bronchospasm 
(Singh & Agrawal, 1990) 
Bupleurum 
falcatum 
Roots 
saikosaponin-A 
(SSA), 
triterpenoid 
glycoside. 
Inhibited the passive cutaneous 
anaphylaxis reaction in rats & 
antagonism of the histamine action and 
inhibition of allergic mediators (Park et 
al., 2002). 
Benincasa 
hispida 
Fruit Pulp Metanolic Extract 
Histamine & Ach Induced 
Bronchospasm(Anilkumar D., 
Ramu,2002) 
Boswellia serrata Root 
Boswellin, boswellic 
acids 
Inhibit LT biosynthesis and block 
synthesis of 5-HETE & LTB4 
(Gupta,1998) 
Curcuma longa Rhizome 
Tumerones, 
curcuminoids 
Inhibits histamine release from rat 
peritoneal mast cells (Ammon & 
Wahl,1991) 
Eugenia 
caryophylis 
Flower 
buds, 
leaves 
Eugenol 
Antianaphylaxis, inhibits C 48/80 
induced anaphylaxis(Sharadini,1985) 
Picrorhiza kurroa Roots Picrorrhizin 
Inhibits release of histamine and SRS-A 
(Doshi & Shetge, 1983) 
Solanum 
xanthocarpum 
Herb Salasodin 
Bronchodilator (Govindan & 
Viswanathan, 1999) 
Tenospora. 
 cardoifofia 
Stem Aqueous extract 
Mast cell stabilizing activity 
(Nayampalli & Desai,1986) 
Tamarandus  
indica 
Whole 
plant 
Indolizidine 
alkaloid. 
Bronchodilatory, membrane stabilizing 
(Sharadini,1985) 
Vitex. negundo Leaves Alcoholic extract 
Bronchodilatory, membrane stabilizing 
(Saraf & Nair,1995) 
Calotropis  
gigantea 
Flower 
& calotropeol, -
amyrin, ,giganteol 
Bronchodilator anti-inflammatory 
(Sangraula and Kumar 1999) 
Calotropis 
procera 
Flower 
& calotropeol, 
-amyrin, giganteol 
Bronchodilator anti-inflammatory 
(Sangraula and Kumar 1999) 
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Plant Part used 
Extract/Active 
principle 
Probable action in asthma 
Cedrus deodara Wood Himacholol 
Mast cell stabilizing activity (Shinde et 
al., 1999) 
Centipeda 
minima 
Whole 
plant 
Pseudoguainolid,ses
quiterpen,lactones, 
flavonoids 
Inhibits passive cutaneous anaphylaxis 
in rats (Wu et al., 1985) 
Clerodendrum 
serratum 
Leaves Aqueous extract. Bronchodilator (Gupta, S.S., 1994) 
Inula. racemosa Roots Aqueous, alcoholic 
Anti-histaminic, Anti-serotonergic 
(Srivastava et al., 1999) 
Sarcostemm 
brevistigma 
Twigs Alkaloid fraction 
Inhibits passive cutaneous anaphylaxis 
in rates (Saraf and Patwardhan,1998) 
Tephrosia 
purpurea 
Whole 
plant 
Ethanolic extract 
Bronchodilatory, antianaphylactic 
(Gokhale and Saraf,2000) 
Table 3. 
7. Bronchodilator activity of two combined component of alkaloidal fraction 
of Ailanthus excelsa Roxb 
Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a 
total that is expected to rise to about 400 million over the next 15–20 years (Kumar et al., 
2010a) Ailanthus is a deciduous tree belonging to the family Simarubaceae, and widely 
distributed in Asia and North Australia. Commonly it is known as a Plant of Heaven. The 
bark of this plant is used as an anthelminthic, expectorant, antiasthmic, antispasmodic and 
antipyretic (Kumar et al., 2010b). Ailanthus excelsa is reported to be useful in a many ailments 
like asthma, allergy, bronchoconstriction etc. In the present study two combined 
Component of alkaloidal fraction of stem bark of Ailanthus excelsa Roxb.(AFAE) was for the 
first time evaluated for its bronchodilator activity. 
 
 
Fig. 4. 
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7.1 Materials and methods 
Plant material: Stem barks of Ailanthus excelsa Roxb were collected in Aug. 2008 from local 
area of Pimpri, pune-18 (INDIA) and identified by the RRI of Ayurveda Kothrude, Pune 
(INDIA). A voucher specimen - 899 was authenticated. Stem barks were dried, powdered, 
passed through 40 mesh sieve. The powdered material was extracted with methanol (95%) 
using soxhlet apparatus (10%). The brown extract (2gm) of stem bark of Ailanthus excelsa 
roxb. was used to prepare an alkaloidal rich fraction. The alkaloidal fraction was 500 mg and 
this Alkaloidal fraction was subjected to column chromatography for isolation of pure 
constituents using different polarity solvent and silica (60-120) as adsorbent. The component 
was isolated in chloroform: methanol (4:1) proportion (50 mg) and the same was checked for 
its purity by performing TLC in Beznene: methanol (4:1) solvent system. A single spot with 
Rf value of 0.56 was recorded. The isolated sample was then subjected to GC-MS which 
however showed the same to be a mixure of two components having close resemblance to 
each other and the fragmentation pattern was almost same and the retention time gap was 
very small. The molecular weights were 413 and 429. Alkaoidal tests were positive for the 
constituents.  
Animal: Albino rats (Wistar strain) and mice (musmusculus strain) of either sex weighing 
150-200gm rats and 20-25gm mice respectively were used. They were housed in microlon 
boxes with standard laboratory diet and water ad libitum. The study was conducted after 
obtaining Institutional Animal Ethical Committee clearance (198/99/CPCSEA). 
Acute toxicity studies: AFAE was safe upto 1000mg/kg and based on the results of 
preliminary toxicity testing the doses of 10, 20 and 40mg/kg p.o were chosen for further 
experiments. 
7.2 Bronchodilator activity 
Effect of test drug on isolated goat trachea chain preparation: Isolated adult Goat tracheal 
tissue was obtained immediately after slaughter of the animals. Trachea was cut into 
individual rings and tied together in series to form a chain. Trachea was suspended in bath 
of Kreb’s solution which was continuously aerated and maintained at 37 ± 0.5 ºC. Tissue was 
allowed to equilibrate for 45 min. under a load of 400 mg. A dose response curve for 
histamine was taken in variant molar concentrations, by maintaining 15 min time cycle. 
After obtaining a dose response curve of histamine on trachea, the AFAE was added to the 
respective reservoir and same doses of histamine were repeated. Graph of percentage of 
maximum contractile response on ordinate and negative logarithm of molar concentration 
of histamine on abscissa were plotted to record dose response curve of histamine, in absence 
and in presence AFAE (Bhujbal et al., 2009). 
Milk induced leukocytosis and eosinophilia: Mice were divided into five groups, six 
animals in each group. Animals belonging to group-I received distilled water (DW) 10 
ml/kg, (p.o.). Animals belonging to group II, III, IV, V received boiled and cooled milk 
injection in dose of 4 ml/kg, (s.c.). Animals belonging to groups III, IV and V received 
AFAE in dose 10, 20 and 400 mg/kg, p. o. respectively, 1 hr before milk injection. Blood 
samples were collected from each mouse from the retro orbital plexus, under light ether 
anaesthesia. Total leukocyte count and total eosinophilia count was done in each group 
before drug administration and 24 hr after milk injection. Difference in Total leukocyte 
count and total eosinophilia count before and 24hr after drug administration was 
calculated. 
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Clonidine-induced Mast Cell Degranulation: Rats were divided into five groups, six 
animals in each group. Animals belonging to group-I received vehicles 5 ml/kg, (p.o.) 
Animals belonging to group-II received Sodium cromoglycate 50 mg/kg, (i.p.). Animals 
belonging to group-III, IV and V received AFAE in dose (10, 20 and 40mg/kg, p.o.) 
respectively. The treatment was continued for 7 days. On day 7 th, 2 hour after the 
assigned treatment mast cells were collected from the peritoneal cavity. 10 ml of normal 
saline solution was injected into peritoneal cavity and abdomen was gently massaged for 
90 second. The peritoneal cavity was carefully opened and the fluid containing mast cells 
was aspirated and collected in siliconised test tube containing 7 to 10 ml of RPMI-1640 
Medium (pH 7.2- 7.4). The mast cells were then washed thrice by centrifugation at low 
speed (400-500 rpm) and the pallet of mast cells were taken in the medium. The mast cells 
suspension approximately (1 x 10 6 cells/ml) was challenged with 0.5 µg/ml of clonidine 
solution and stained with 1 % toluidine blue and observed under high power microscope 
field (400 X). Total 100 cells were counted from different visual areas and the number of 
intact and degranulated cells was counted. The percent protection was calculated (Kumar 
et al., 2009). 
Bronchoalveolar lavage and lung histology in rats: Animals were divided into five 
groups each group containing six animals. All the animals were sensitized by an 
intraperitoneal injection of 1ml alum precipitate antigen containing 20µg of ovaalbumin 
and 8mg of alum suspended in 0.9% sodium chloride solution. A booster injection of this 
alum-ovalbumin mixture was given 7 days later. Non sensitized animals were injected 
with alum only. Seven days after (15th day) second injection animals were exposed to 
aerosolized ovaalbumin(1%) for 30 min. Standard & test group was received 
Dexamethasone (1mg/kg, i.p.) as standard and AFAE 10, 20, 40mg/kg as test drug, 5 hr 
before antigen challenge. The rats were sacrificed at the end of study (24 hr after 
sensitization) and tracheal catheter was inserted in trachea. Bronchoalveolar lavage fluid 
was collected by lavaging the lung with 2 aquilots of 5 ml of 0.9% sodium chloride 
solution total recovery volume per rat was approximately 8ml. Total leukocytes and 
eosinophiles, neutrophiles were counted under microscope and  Histopathological 
evaluation of  lung tissue was carried out (Kumar et al, 2010c). 
7.3 Statistical analysis 
All values were expressed as mean± S.E.M. and data were analysed by ANOVAs followed 
by dennest. 
8. Results 
 
Fraction 
quantity 
Solvent 
proportion 
Yield 
(mg) 
colour Identification test
TLC benzene: 
methanol (4:1) 
500mg 
Chloroform: 
methanol (80:20)
50 mg brown 
UV- 365 flurosent, 
positive for 
alkaloids 
Single spot with Rf 
value - 0.56. 
Table 4. Isolation and Characterization of AFAE 
a. Alkaloidal fraction: U.V spectroscopy: UV λ max. –282, 242, 220, IR range: 
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b. AFAE: U.V spectroscopy:  UV λ max. – 209, 220, IR range: 
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Fig. 6. 
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GC-MS 
Fig. 7. The above compounds having very less retention time and they have similar ion 
peaks so in their structure there may be the possibilities of similarity. 
8.1 Bronchodilator activity: In vitro 
Effect of AFEA (30µg/ml) on Histamine induced contraction of isolated goat tracheal 
chain preparation: In the present study, it was observed that AFAE inhibits the contraction 
produced by histamine in these tissue preparations. Histamine (10µg/ml) was taken in 
different dose level and DRC was plotted in absence and in presence of Ailanthus excelsa 
extract. Study showed that AFAE inhibits significantly (*p<0.05, **p<0.01, ***p<0.001) 
percentage contraction at concentration 30µg/ml in goat tracheal chain preparation. Dose 
dependent response relationship was seen (Figure 8). 
 
 
n = 6, Values are in Mean  SEM. Control = D.R.C. of Histamine in absence of AFAE. AFAE = D.R.C. of 
Histamine in presence of AFAE (30µg/ml). Statistical analysis done by using Student’s‘t’-test. (*p<0.05, 
**p<0.01, ***p<0.001), significantly different from control.  
Fig. 8.  
8.2 In - vivo 
Milk induced leukocytosis and eosinophilia: Subcutaneous injection of milk at dose of 4 
ml/kg produced a significant (***p< 0.001) increase in the leucocytes and eosinophiles count 
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after 24 hr of its administration. In the groups of mice pretreated with AFAE at dose (10 
mg/kg, 20 mg/kg and 40 mg/kg, p.o.), there was significant (*p<0.05, **p<0.01) inhibition 
of milk-induced Leucocytosis and eosinophilia (Figure 9 & 10). 
 
 
n= 6, values are expressed in mean±SEM. Control = Vehicle (10 ml/kg, p.o.). Intox.    = milk 4 ml/kg, 
***p<0.001, Intox. group compared with control group using student’t, test and *p< 0.05, **p<0.01, 
AFAE compared to intox. Group using Statistical analysis done by ANOVA followed by Dunnet’s test. 
Fig. 9. Effect of AFAE on TLC count 
 
 
n= 6, values are expressed in mean±SEM. Control = Vehicle (10 ml/kg, p.o.). Intox.    = milk 4 ml/kg, 
***p<0.001, Intox. group compared with control group using student’t, test and *p< 0.05, **p<0.01, 
AFAE compared to intox. Group using Statistical analysis done by ANOVA followed by Dunnet’s test. 
Fig. 10. Effect of AFAE on TEC 
Effect of AFAE on clonidine-induced mast cell degranulation in rats: Clonidine induced 
mast cell degranulation was significantly (**p<0.01) inhibited by sodium cromoglycate (50 
mg/kg, i.p.) and percent protection was found to be 68.42%. In the groups pre-treated AFAE 
(10, 20, 40 mg/kg, p.o) there was significant protection (**p< 0.01) of mast cells and the 
percent protection was 37.89, 54.21, and 61.42 % respectively (Figure 11). 
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n= 6, values are expressed in mean±SEM. Control = Distilled water (5 ml/kg, p.o.). Std. = Sodium 
cromoglycate (50 mg/kg, i.p.), Std., AFAE10, AFAE20, AFAE40 compared with Control (ANOVA 
followed by Dunnett’s test), **p < 0.01. 
Fig. 11. Effect of AFAE on Clonidine-induced Mast cell Degranulation in rats 
Effect of AFAE on Bronchoalveolar lavage in rats: Persistent mucosal airway inflammation, 
associated with an increase in T helper type 2 (Th2) cytokine levels, eosinophil infiltration 
into the airways, and mucus and immunoglobulin (IgE) production, are the main features of 
allergic asthma. The infiltration of cells like eosinophils, neutrophils, monocytes, 
macrophages, lymphocytes, etc., increases the allergic asthmatic effect. Injection of 
ovalbumin 20 µg + 8 mg alum in 1 ml (i.p.) on days 1 and 7 and 1% OVA aerosol on 15th 
day produced a significant (***P < 0.001) increase in the TLC. In the groups pretreated with 
standard drug dexamethasone (1 mg/kg i.p.), there was a significant (**P < 0.01) inhibition 
of ovalbumin-induced TLC and differential leukocyte count. The AFAE at doses of 10, 20, 
and 40mg/kg showed significant decrease in TLC and neutrophils, lymphocytes and 
monocytes, macrophages and eosinophils (*P < 0.05, **P < 0.01 [Table 5]. AFAE40 
 
Sr. 
No. 
Groups 
Recoverable BAL Cells (×103/µl)(Mean ± SEM) 
Total Cells Neutrophile Eosinophils Lymphoctes Monocytes 
Alveolar 
Macrophages 
1. NS 186 ± 8.12 19.6 ± 3.69 13 ± 1.55 6 ± 1.34 4 ± 0.71 4.8 ± 0.58 
2. S 820 ± 57.09*** 122 ± 10.08*** 79.8 ± 4.13*** 39.2 ± 3.8*** 19.8 ± .74*** 16.6 ± 1.08*** 
3. Std 218 ±7.84** 52.6 ± 1.17** 32.4 ± 3.98** 10.6 ± 0.66** 6.8 ± 0.66** 6.2 ± 1.36** 
4. AFAE10 384 ±  24.97** 98.4 ± 7.17* 66 ± 4.44 18.4 ± 2.06** 13 ± 1.05** 12 ± 0.71 
5. AFAE20 322 ± 26.91** 76.8 ± 3.61** 56.2 ± 2.71** 18.6 ± 1.03** 12 ± 0.95** 13.2 ± 0.97** 
6. AFAE40 246 ± 12.39** 66.2 ± 3.64** 45.2 ± 4.83** 13.3 ± 1.50** 9.4 ± 0.86** 9.6 ± 0.81** 
n= 6, values are expressed in mean±SEM. NS =  Non Sensitized group, Distilled water + 8mg alum in 1 
ml (i.p.). S = Sensitized group, Ovaalbumin20µg+8mg alum in 1ml (i.p.) 1,7 day and 1% OVA aerosol on 
15 day. Std. = Dexamethasone (1mg/kg, i.p.). NS compared with S by using student’t, test***p < 0.001 
and Std., AFAE10, AFAE20, AFAE40 compared with S (ANOVA followed by Dunnett’s test), *p < 0.05, 
**p < 0.01. 
Table 5. Effect of AFAE on Bronchoalveolar lavage in rats 
www.intechopen.com
 Bronchodilator Activity in Traditional Medicines: Gift of God Kingdom 
 
187 
Effect of AFAE on Histopathological evaluation of Lung Tissue: The histopathological 
evaluation of lung tissue showed the reduction of inflateration and mediators of 
brnchoconstruction. The AFAE showed significant bronchodilator activity. Light 
micrograph of rat lungs collected from different treatment groups and the lungs were fixed 
in formalin and embedded in paraffin wax. Section of lung tissue were cut at 5μm thickness, 
mounted on glass slides, stained with hematoxylin and eosin (H × E) and cells were 
identified as either eosinophils, neutrophils or mononuclear cells by standard  morphology 
and 200 cells counted under 400X magnification (Figure 12). 
 
 
Fig. 12. Effect of AFAE on histopathological evaluation of lung tissue. 
Where a) = Abscence of imfalmmatory cells, no edema in the lung tissue (NS- Non 
sensitized). b) = Abscess formation, fluid accumulation along with inflammatory cells, blood 
cells, edema (S- Sensitized). c) = a low magnification lung section from an antigen- 
challenged animals received (standard) dexamethasone (1mg/kg i.p.) showing abscence of 
fluid accumulaton around the blood vessel. d) = AFAE10 showing haemorrhages, 
emphysema, MNC and edema. e) = AFAE20 showing emphysema, MNC and 
haemorrhages. f) = AFAE40 showing emphysema. 
9. Discussion 
The role of plants serving as purifiers of air has been known to us, since times immemorial. 
To cope with the gradually increasing levels of toxic pollutants, tree plantation programs 
have been undertaken in different countries of the world to help in environmental cleanup. 
Ailanthus excelsa Roxb. (Simaroubaceae) is one such exotic avenue tree, the plantation of 
which has been encouraged under social forestry programs for large-scale tree plantation in 
different densely populated cities and towns of India [Mondal et al., 2007]. Histamine 
contracts the tracheobronchial muscle of guinea pig, goat, horse, dog and man. Goat tracheal 
chain is easier to handle and to prepare; it is also much more sensitive than guinea pig 
tracheal chain. Therefore, the dose relative contractile responses of different agonists like 
ACh, histamine, 5hydroxytryptamine and bradykinin can be observed in isolated goat 
trachea. In the present study the isolated goat tracheal chain preparation; there is right side 
shift of Dose Response Curve (DRC) of histamine in the presence of AFAE indicating 
Bronchodilation [Bhujbal et al., 2009]. In the rat mast cell granules, the histamine 
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concentration has been calculated to be around 0.3 M. Both clonidine and compound 48/80 
act through the dynamic expulsion of granules without causing any damage to the cell wall. 
Clonidine releases histamine from mast cells in a similar manner to a selective liberator like 
compound 48/80 [Lakdawala et al., 1980]. It is known that sodium cromoglycate; a standard 
mast cell stabilizer prevents degranulation of mast cells by raising the cyclic adenosine 
monophosphate. It has been known that all pharmacological agents that increase 
intracellular levels of cAMP relax airway smooth muscle and inhibit the release of autocoids 
from the tissue and basophils. The groups of animals pre-treated with AFAE resulted in a 
significant reduction in degranulation of mast cells and offered significant protection when 
challenged with clonidine indicating mast cell stabilizing activity which ultimately produces 
bronchodilation. The inflammatory response is characterized by an increase in the numbers 
of eosinophils and mast cells, mucus hypersecretion, and activation of T cells. Several 
studies have shown that T-helper type (Th2) cells play a major role in the initiation and 
maintenance of allergic airway inflammation and asthma through their increased 
production of Th2-type cytokines (IL-4, IL-5, and IL- 13). These inflammatory cytokines also 
produced in the bronchial tissue by mast cells, alveolar macrophages, and epithelial cells, 
play a significant role in the pathogenesis of airway inflammation. The inflammatory 
mediators produce bronchoconstriction and the PAE helps to reduce the mediator which 
leads to bronchodilation. Ovalbumin increases the neutrophils, eosinophils, macrophages, 
monocytes, leukocytes, lymphocytes, epithelial cells, mucus etc., in BALF and AFAE helps 
to reduce all the allergic factors [Kumar ett al., 2010c]. 
Thus, it can be concluded from the results obtained in the present investigation that AFAE 
possesses significant bronchodilating activity. Hence, further detailed study needs to be 
conducted to separate the constituents and individually evaluate these phytoconstituent 
responsible to produce the above result and their clinical efficacy in the treatment of 
asthmatic patients. 
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